Norwegian Microemboli in Acute Stroke Study (NOR-MASS)
Norwegian Microemboli in Acute Stroke Study (NOR-MASS)
BACKGROUND: The cause of ischemic stroke remains undetermined in 30-40% of the cases, but circulating blood clots (thromboemboli) are a postulated common denominator in approx. 75% of patients. Transcranial Doppler monitoring (TCDM) is a non-invasive method of detecting circulating microemboli (CME) in the human cerebral circulation. The method is not used systematically in unselected groups of patients with repeated long-term registrations. New ultrasound equipment is ambulatory, less unpleasant for the patient and allows extended monitoring sessions. This may vastly simplify the implementation of TCDM as a clinically useful diagnostic tool.
AIMS: Determine the usefulness of TCDM in acute stroke diagnostics by assessing prevalence and frequency of CME in unselected patients with ischemic stroke, the influence of antithrombotic drugs on CME and the relationship between MES and recurrent stroke or transient ischemic attack (TIA).
HYPOTHESES: Prevalence and frequency of CME are higher during the first 24 hours than at later follow-up. Stroke etiology can be assessed by the presence or absence of CME. Presence of CME is associated with increased risk of recurrent TIA of stroke within 3 months and 1 year. Cessation of CME after the start of antithrombotic treatment is associated with reduced risk of recurrent TIA or stroke.
研究概览
详细说明
- Standardized questionnaire
- Clinical work-up in accordance with hospital standard operating procedures, i.e. radiological and cardiological procedures, neurovascular ultrasound, clinical scoring, etc.
- 1st Transcranial Doppler monitoring (TCDM) at admission if within 24 hours after stroke onset (day 1). TCDM is repeated at 18-36 hours and at day 3. Microembolic signals are automatically registered by the software and subsequently verified manually.
研究类型
注册 (预期的)
联系人和位置
学习联系方式
- 姓名:Sander Aarli, MD
- 电话号码:+4799557918
- 邮箱:drar@helse-bergen.no
研究联系人备份
- 姓名:Annette Fromm, MD, PhD
- 邮箱:atfm@helse-bergen.no
学习地点
-
-
-
Bergen、挪威、5021
- 招聘中
- Haukeland University Hospital
-
接触:
- Sander Aarli, MD
- 电话号码:+4799557918
- 邮箱:drar@helse-bergen.no
-
接触:
- Annette Fromm, MD, PhD
- 邮箱:atfm@helse-bergen.no
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Admitted to hospital < 24 hours after onset of ischemic stroke
Exclusion Criteria:
- Temporal bone window inadequate for transcranial Doppler examination
- Participation in ongoing sonothrombolysis study (NOR-SASS 2)
- Reduced ability to cooperate
- No informed consent can be obtained
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Prevalence of circulating microemboli
大体时间:Up to 24 hours after symptom onset
|
Up to 24 hours after symptom onset
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Prevalence of circulating microemboli as a function of time and antithrombotic drugs
大体时间:3 days after symptom onset
|
3 days after symptom onset
|
Prevalence of MRI DWI lesions
大体时间:18-36 hours after symptom onset
|
18-36 hours after symptom onset
|
Recurrence of ischemic stroke/TIA
大体时间:3 months
|
3 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.